Abgenix Partners With SangStat On GVHD Work.(graft-vs-host disease )(Brief Article)

For marketing and development of its antibody for steroid-resistant graft-vs-host disease (GVHD). pairing up with SangStat Medical Corp. seemed a natural move for Abgenix Inc. And that's just what the company did. In an agreement that includes milestone payments and royalties, in addition to an up-front license fee. Abgenix signed over global distribution rights to ABX-CBL, an anti-CD147 monoclonal antibody- We're very pleased to be working with SangStat. which is a …